Pharmaceutics (Jan 2022)

Tracking Radiolabeled Endothelial Microvesicles Predicts Their Therapeutic Efficacy: A Proof-of-Concept Study in Peripheral Ischemia Mouse Model Using SPECT/CT Imaging

  • Romain Giraud,
  • Anaïs Moyon,
  • Stéphanie Simoncini,
  • Anne-Claire Duchez,
  • Vincent Nail,
  • Corinne Chareyre,
  • Ahlem Bouhlel,
  • Laure Balasse,
  • Samantha Fernandez,
  • Loris Vallier,
  • Guillaume Hache,
  • Florence Sabatier,
  • Françoise Dignat-George,
  • Romaric Lacroix,
  • Benjamin Guillet,
  • Philippe Garrigue

DOI
https://doi.org/10.3390/pharmaceutics14010121
Journal volume & issue
Vol. 14, no. 1
p. 121

Abstract

Read online

Microvesicles, so-called endothelial large extracellular vesicles (LEVs), are of great interest as biological markers and cell-free biotherapies in cardiovascular and oncologic diseases. However, their therapeutic perspectives remain limited due to the lack of reliable data regarding their systemic biodistribution after intravenous administration. Methods: Applied to a mouse model of peripheral ischemia, radiolabeled endothelial LEVs were tracked and their in vivo whole-body distribution was quantified by microSPECT/CT imaging. Hindlimb perfusion was followed by LASER Doppler and motility impairment function was evaluated up to day 28 post-ischemia. Results: Early and specific homing of LEVs to ischemic hind limbs was quantified on the day of ischemia and positively correlated with reperfusion intensity at a later stage on day 28 after ischemia, associated with an improved motility function. Conclusions: This concept is a major asset for investigating the biodistribution of LEVs issued from other cell types, including cancer, thus partly contributing to better knowledge and understanding of their fate after injection.

Keywords